It's time to follow Mannkind's approach to remain silent and share little information. I will continue to hold all my shares in Mannkind and hope we all have a lot to celebrate in the near term. I will now focus more time on my other investments especially Citigroup, which appears ready to break out to the upside. Good luck !
crs2919 I have no problem posting my opinions in a balanced manner and if you have a problem with it just put me on ignore and don't tell me what I should do.
ricemba1965....the stock price is trading $7, which is 40% lower then its 52 week high and worse yet, Mannkind's poor PR i allowing Sierra to continue its pathetic speculation about the company.
Since when is disclosing good news early a negative for share holder value ? Also they don't have to release material information to be transparent and present a clear & concise message about the company's activities.
Alfred Mann could have cut a deal with big pharma to raise capital that had them fund all or part of the last Phase III trials, instead of entering into dilutive deals with Alfred Mann's financial arm Mannkind Group that issued warrants that diluted shareholder value by as much as 90 million shares all that went to Alfred Mann. I also don't like the huge stock options given to management.
Let's see if a new Mannkind PR initiative emerges after the quiet period ends ? I am now having some doubts about the effort Mannkind will put forth after the quiet period in order to create shareholder value. As long as Bank of America continues to hold onto the 9 million shares of Mannkind stock Alfred Mann loan them, I will question the conflict of interest Al has as CEO & Chairman of Mannkind and his personal Private Banking Customer relationship with Bank of America.
mike.. ethically as CEO/Chairman of a publicly traded company, Alfred Mann's first priority is to his shareholders and creating shareholder value and all the other stuff you mentioned like money not driving him should only apply to his decisions being for for his private company's and organizations like the Alfred Mann Foundation. As CEO & Chairman, Alfred Mann needs to first create and deliver shareholder value and so far he has delivered extensive shareholder dilution that seems to have benefited him more than his shareholders. JMO
Mannkind needs to open up about the company's future plans and financial forecast for revenues, cash flow and profitability. Their continued silence surround those important topics and their vagueness surround other company matter is no longer acceptable. Insiders need to start sharing what they know with the rest of us.
I hope you're right, but I am becoming weary about management and I don't trust Alfred Mann. I think Al has his own agenda and we longs may not see the kind of return we are hoping. Seems like Wall Street also wants to see the company sold.
In addition it also looks likes a right of first refusal is not part of the Sanofi deal. Looks like Mannkind made sure it keep itself free of any ownership conflict coming from the Sanofi deal to allow another deal to be closed. As to what the other deal may look like, there are may possible scenario's. Good luck longs.
I don't believe Mannkind's shares would drop upon the transfer of Technopshere and Devices to Medallion, because I don't think either one of them are currently impacting Mannkind's market cap or share price to a great extent. I think the deal along with clarity about Mannkind's licensing/collaboration agreement with Sanofi will create greater shareholder value for Mannkind shareholders
I did not say I think anything will happen on Tuesday other than an HSR approval that will end the quiet period. I hope Mannkind announces when the HSR period expires.
I tried to send 3 replies including a test and they never appeared.
Our Chairman and Chief Executive Officer and principal stockholder can individually control our direction and policies, and his interests may be adverse to the interests of our other stockholders. After his death, his stock will be left to his funding foundations for distribution to various charities, and we cannot assure you of the manner in which those entities will manage their holdings.*
At June 30, 2014, our Chairman and Chief Executive Officer, Alfred E. Mann beneficially owned 38.7% of our outstanding shares of capital stock. By virtue of his holdings, Mr. Mann may be able to continue to effectively control the election of the members of our board of directors, our management and our affairs and prevent corporate transactions such as mergers, consolidations or the sale of all or substantially all of our assets that may be favorable from our standpoint or that of our other stockholders or cause a transaction that we or our other stockholders may view as unfavorable.
Subject to compliance with United States federal and state securities laws, Mr. Mann is free to sell the shares of our stock he holds at any time. Upon his death, we have been advised by Mr. Mann that his shares of our capital stock will be left to the Alfred E. Mann Medical Research Organization, or AEMMRO, and AEM Foundation for Biomedical Engineering, or AEMFBE, not-for-profit medical research foundations that serve as funding organizations for Mr. Mann’s various charities, including the Alfred Mann Foundation, or AMF, and the Alfred Mann Institutes at the University of Southern California, the Technion-Israel Institute of Technology, and Purdue University, and that may serve as funding organizations for any other charities that he may establish. The AEMMRO is a membership foundation consisting of six members, including Mr. Mann, his wife, three of his children and Dr. Joseph Schulman, the chief scientist of the AEMFBE. The AEMFBE is a membership foundation consisting of five members, including
28903 North Ave. Pine
Valencia, CA 91355
25134 Rye Canyon Loop
Santa Clarita, CA 91355
Sanofi deal was announced on Monday August 11th and HSR approval could/should come by next Tuesday August 26th ending the quiet period. It could even happen earlier. Good luck longs !
Sanofi already has a well seasoned diabetes Specialty & GP sales force in place in the U.S. and the only training necessary will focus on the products features/benefits and sales strategy. That should take no more then 6 to 8 weeks to complete will have the sales force ready to hit the U.S. marketplace selling by November 2014.
There is no way the stock should be trading at this anemic price and it seems obvious the big boys are holding it back to allow a bigger deal to be completed shortly. The Sanofi deal is not the only thing going on behind the scenes. HSR waiting period cannot expire soon enough to find out where this all plays out.